Ionis drug eplontersen trial misses primary cardiac endpoint

The CARDIO-TTRansform trial for eplontersen did not meet its primary cardiovascular endpoint vs. placebo, though a positive signal was seen in monotherapy. The missed readout presents a setback for the drug's add-on therapy strategy, potentially weighing on the stock despite positive pipeline outlook.